VIYASHNSE11 February 2025

Sequent Scientific Limited has informed the Exchange about Investor Presentation

Viyash Scientific Limited

Proven Ability In Life Sciences

February 11, 2025

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001.

National Stock Exchange of India Limited Listing Department Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051.

Scrip code: 512529

Dear Sir/ Madam,

Symbol: SEQUENT

Subject: Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the

quarter and nine month ended December 31, 2024.

Pursuant to Regulation 30 (read with Part A of Schedule III), we are enclosing herewith the Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter and nine month ended December 31, 2024.

Thanking you,

Yours faithfully, For Sequent Scientific Limited

Yoshita Vora Company Secretary

Encl.: A/a

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra, India Tel No.: +91-22-4111-4777 I CIN: L99999MH1985PLC036685 Website: http://www.sequent.in I Email Id: investorrelations@sequent.in

SeQuent Scientific Limited

INVESTOR PRESENTATION Q3 FY25

S E Q U E N T S C I E N T I F I C L I M I T E D

11th Feb 2025

Sequent Q3 FY25 – Continued growth in revenue and profitability

The performance of SeQuent in Q3 FY25 continues to build on the company’s strong return to growth and profitability across all parts of the business. We remain positive on the sustenance of the current momentum. This is further strengthened by the continuing growth of the Viyash business, as we prepare to build a differentiated global pharmaceuticals platform with end to end capabilities .

Our Q3FY25 revenues saw a growth of 18.7% Year-on-Year (“YoY”) to Rs 3,908 mn with strong double digit growth in both Formulations and API. When aggregated for the first nine months the overall revenue growth of the company is at 14.0 % YoY. Our gross margins have continued to trend upwards as we register the benefits of pricing, product mix and market expansion. The ongoing initiatives of cost improvement have further helped in the improvement in profitability. Our EBITDA (pre-esop) of INR 494 Mn represents a 63.8% growth YoY for the quarter, while the first nine months EBITDA (pre-esop) at Rs 1424 Mn showed a growth of 116.5% YoY. The global formulations business grew at 19.8% YoY for the quarter, driven by volume growth in Europe, better product mix in Turkey, and field expansion in India. The API business witnessed strong interest in the deworming segment, and registered a YOY revenue growth 17.7 % for the quarter. Our facilities in Turkey and Mahad received approvals of global agencies, thereby strengthening their readiness to service new customers.

In September 2024, we announced the proposal for a strategic merger with Viyash Life Sciences Private Limited (“Viyash”). We have begun to receive some key approvals from regulatory agencies and expect to complete the process before December 2025, subject to statutory approvals. Viyash Life Sciences continues to deliver strong performance , with a revenue growth of 19% YoY for Q3 FY25 and EBITDA ( pre Esop ) growth of 68% YoY for this quarter, while accelerating the rate of new filings and new product launches. We are very excited about the potential of the merged entity, which will create a strong R&D engine for growth, improve margins and enhance our Go to Market capabilities.

Rajaram Narayanan

Managing Director and CEO

SeQuent & Viyash : Proforma Q3FY25 Combined Performance

Q3 FY25 Performance Highlights

Revenues

EBITDA (pre- ESOP)1

EBITDA margin

All values in ₹ Mn

Net Debt to LTM Adj. EBITDA1

₹7,747 Million

₹1,179 Million

15.2%

1.2x

18.8% YoY

66.3% YoY

435 bps YoY

vs. 1.4x in Q2FY25

Proforma Q3FY25 Combined Performance

Notes: 1. EBITDA for Viyash is adjusted for ESOP costs, accelerated vesting of warrants, call option charge and merger expenses and includes Forex gains; EBITDA for SeQuent is adjusted for ESOP Costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

9M FY25 Performance Highlights

Revenues

EBITDA (pre- ESOP)1

EBITDA margin

All values in ₹ Mn

Net Debt to LTM Adj. EBITDA1

₹22,369 Million

₹3,317 Million

14.8%

1.2x

12.0% YoY

66.6% YoY

485 bps YoY

vs. 1.4x in Q2FY25

Proforma Q3FY25 Combined Performance

SeQuent : Q3FY25 Performance Update

Q3 FY25 Performance Highlights – Sustained Revenue and Profit Growth Strengthening Our Position

All values in ₹ Mn

Revenues

EBITDA (Pre ESOP)

EBITDA margin

PBT

₹3,908 Million

18.7% YoY

₹494 Million

63.8% YoY

12.6%

348 bps YoY

₹81 Million

444% YoY

9M FY25 - Robust Revenue and EBITDA Growth, Fueling Momentum for a Successful Year

All values in ₹ Mn

Revenues

EBITDA (Pre ESOP)

EBITDA margin

PBT

₹11,497 Million

₹1,424 Million

14.0% YoY

116.5% YoY

12.4%

590 bps YoY

₹280 Million

149% YoY

SeQuent : Q3 FY25: Revenue Performance – by geography

All values in ₹ Mn

Revenue Distribution

Formulations

Europe

Emerging Markets

India

APIs

Other Sales

Global Sales One Offs #

Adjustment* - Ind AS 29*

Q3 FY25 Q2 FY25 QnQ Gr% 2,836 1,335 1,160 341 773 22 3,631

6.1% 0.0% 17.8% -9.9% 5.0% 3.4% 5.8%

3,008 1,334 1,366 308 812 23 3,843

13 43 3,686

65 3,908

QnQ Gr% (In cc) 8.9% 3.0% 21.1% -9.9% 4.5% 3.4% 7.9%

8.0%

Q3 FY24 YoY Gr%

YoY Gr% (In cc) 19.2% 4.6% 40.8% 10.7% 16.1% -46.8% 17.4%

9M FY25 9M FY24 YoY Gr% 7,520 3,631 3,084 805 2,301 96 9,917

17.7% 16.8% 20.4% 10.9% 9.0% -13.2% 15.4%

8,849 4,241 3,714 893 2,509 83 11,441

YoY Gr% (In cc) 21.9% 15.3% 32.6% 10.9% 7.8% -13.2% 18.0%

19.8% 5.2% 41.8% 10.7% 17.7% -46.8% 18.5%

18.7%

17.6%

(74) 130 11,497

168 10,085

14.0%

16.6%

2,510 1,269 963 278 690 43 3,243

51 3,294

Reported Sales # Provision for customer claim on shipments in prior years

6.0%

•

Europe Volume growth and improved product mix.

Emerging Markets: : Turkey sales growth is driven by recovery of volume losses and selective price increases

India: Steady growth YoY owing to Project Udaan (field expansion) . QnQ degrowth is inline with seasonality impact

API : Increase in sales from deworming portfolio

*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

SeQuent Scientific Limited 9

SeQuent : Q3 FY25 Business Performance

All values in ₹ Mn

Europe: Turkish GMP certification received

Emerging Markets: Business restructuring focused on volume recovery

Formulations

LATAM: Strong growth driven by strategic portfolio focus

India : Project Udaan field expansion

WHO Prequalification Achieved: Officially listed in the WHO API Prequalification database

API

Regulatory Milestone: Successfully received a new CEP approval this quarter

Safety Recognition: Mahad site awarded the NSCI Safety Award 2024 (Manufacturing Sector)

Second WHO Drug Approval: WHO has approved a customer’s drug product formulated with our API

1,000+ FDFs

90+ Countries

5 Manufacturing Facilities

32 APIs

50+ Countries

2 Manufacturing facilities

SeQuent : Q3 FY25 Consolidated Financials

All values in ₹ Mn

Particulars

Revenue from Operations Material Consumption Gross Margin % Employee Benefit Expenses Operating Expenses EBITDA (pre-ESOP) % ESOP cost EBITDA % Exceptional Items IndAS 29 Adjustment Exchange Gain / (Loss) Other Income Finance Cost Depreciation Earnings Before Tax Taxes* Earnings After Tax Earnings After Tax Adjusted# Of which Minority Interest

8.6%

% 6.0%

8.0% 7.9% 10.5% 4.2%

Q3 Grw QnQ Q2 Q3 FY24 FY25 FY25 3,686 3,294 3,908 (1,953) (1,806) (2,025) 1,734 1,487 1,883 48.2% 47.0% 45.2% (527) (603) (651) (659) (683) (738) 302 447 494 12.6% 12.1% 9.2% (52) (67) (102) 250 380 392 10.0% 10.3% 7.6% (43) 25 (14) 45 (143) (171) 79 (16) 63 63 37

(3) 5 (52) 59 (150) (170) 81 (16) 65 65 30

28 (6) (21) 45 (126) (155) 15 92 107 39 24

2.5% 2.5%

3.2%

2.6%

Grw YoY %

26.6%

57.0%

23.7% 11.9% 63.8% 38.0%

9M FY25 18.7% 11,497 (6,121) 5,376 46.8% (1,834) (2,118) 1,424 12.4% (210) 1,214 10.6% (46) 23 (81) 130 (456) (503) 280 (61) 219 219 93

-39.2% 65.7%

444.1%

NA = Not Applicable

9M FY24 10,085 (5,652) 4,433 44.0% (1,706) (2,069) 658 6.5% (177) 480 4.8% (127) (58) (131) 70 (356) (451) (573) 264 (309) (376) 41

Grw YoY % 14.0%

21.3%

7.5% 2.4% 116.5% 89.9%

152.6%

NA NA

Key Notes :

+ 3.0% Gross Margin and +3.4% EBITA Margin Improvement YoY in Q3 FY25: •Formulations: Timely price increase in Turkey along with closely monitoring the product mix in Europe, focusing on high- margin products API: Cost and operational excellence initiatives under Project Pragati led to an expansion in margins

Operating expenses increase primarily due to higher inflation in Turkey and marketing initiatives aimed at supporting sales growth in Turkey and Europe. Increase in ESOP is on account of additional shares allotted in Sep’24.

*Taxes: In Q3’FY’24 there was one-time significant tax benefit accounted in Turkey due to change in Hyperinflation Accounting methodology as prescribed by Turkey to regulatory authorities which exceptional tax benefit in FY’24 which was pertaining to FY’21, FY’22 and Fy’23

lead

# PAT Growth: Excluding above exception one time Tax benefit in Q3 FY’24 on like-to- like basis there is strong PAT growth as well in Q3 FY’25 and 9M FY’25.

Viyash: Business Update

Viyash: Q3 FY25 – Continued strong performance on revenue, profitability and cashflows

Revenues

Adj. EBITDA1

EBITDA margin

Net Debt to LTM Adj. EBITDA1

₹3,839 Million

19.0% YoY

₹685 Million

68.0% YoY

17.8%

0.4x

520 bps YoY

vs.1.1x In FY24

Notes: 1. EBITDA is adjusted for ESOP costs, accelerated vesting of warrants, call option charge and merger expenses Source: Viyash Life Sciences website published Investor Presentation

Viyash: 9M FY25 – Robust YTD performance

Revenues

Adj. EBITDA1

EBITDA margin

Net Debt to LTM Adj. EBITDA1

₹10,872 Million

₹1,893 Million

17.4%

0.4x

9.9% YoY

42.1% YoY

395 bps YoY

vs.1.1x In FY24

Notes: 1. EBITDA is adjusted for ESOP costs, accelerated vesting of warrants, call option charge and merger expenses Source: Viyash Life Sciences website published Investor Presentation

Key updates from Q3 FY25

Facility Inspections

1 Regulatory Audits 40 Customer audits

Regulatory Approvals

Launches

3 APIs: CEP (2), CA (1) 2 FDFs: US (2)

2 FDFs- US

Products Filed

Validations Completed

R&D Pipeline

03 APIs: USDMF (1), CEP (1), EDMF(1)

4 Validations

25+ products

Source: Viyash Life Sciences website published Investor Presentation

Extensive Manufacturing Capabilities (1/2)

VIYASH UNIT - I

Taloja, Maharashtra API Facility

VIYASH UNIT - II

Containment facility for in-house manufacturing of high potent (OEB 4/5) and cytotoxic API.

Capacity-39KL

USFDA/ EU-GMP/ PMDA/ TGA/ KFDA/ WHO-GMP

Containment facility for in- house manufacturing of cytotoxic APIs,

Capacity 290KL

USFDA/ EU-GMP/ WHO-GMP

SYMED LABS LTD, UNIT-I

Operates in accordance with cGMP

APPCO PHARMA LLC

Capacity-80KL

USFDA/ EU-GMP/ WHO- GMP / KFDA/ ANVISA

Hyderabad, Telangana, API Facility

SYMED LABS LTD, UNIT-II

Expertise in Polymorphic forms

APPCO Pharma LLC FDF Facility, USA

Expertise in OSD

Capacity 1.2 Bn Units

USFDA

Capacity 137KL

USFDA/ COFEPRIS/ EU- GMP / KFDA/ ANVISA

Vizag, A.P API Facility

Hyderabad, Telangana, API Facility

Source: Viyash Life Sciences website published Investor Presentation; Management data & commercial due diligence analysis

Extensive Manufacturing Capabilities (2/2)

SYMED LABS LTD, UNIT-IV

Hyderabad, Telangana, API Facility

SYMED LABS LTD UNIT-VI

Hyderabad, Telangana, Intermediates

Expertise in Grignard, Acid Derivatives carbonylation, Iron Complex reactions, Reduction reactions in Catalytic Media, reactions and Enzymatic ResolutioCyanationn reactions.

Capacity-314KL

USFDA/ EU-GMP/ WHO-GMP

Expertise in Nitration reactions, Reduction reactions in Catalytic Media.

Capacity-490KL

USFDA for Advanced Intermediates/ ANVISA for API/ WHO-GMP

VINDHYA PHARMA

Hyderabad, Telangana, Intermediates

SV LABS

Hyderabad, Telangana, Intermediates

Source: Viyash Life Sciences website published Investor Presentation; Management data & commercial due diligence analysis

Expertise in Grignard, Coupling, Bromination, Hydrolysis, Reduction, Chlorination, Condensation, Acetylation, Friedel-Crafts, Decarboxylation, Demethylation and Oxidation Reactions.

Capacity-266 KL

USFDA for Advanced Intermediates

Expertise in Bromination, Cyanidation, Chlorination, Condensation, Hydrogenation, Reduction, Acetylation, Esterification, Hydrolysis and Friedel-Crafts Reactions.

Capacity-412KL

USFDA for Advanced Intermediates

Viyash: Financial performance

All values in ₹ Mn

Particulars

FY25

FY24

Grw YoY %

FY25

Grw QoQ %

9M YTD

FY25

9M YTD FY242

Grw YoY %

Revenue from Operations

3,839

3,226

19.0%

3,632

5.7%

10,872

9,896

9.9%

Material Consumption

(1,751)

(1,443)

21.4%

(1,624)

7.8%

(4,956)

(4,721)

5.0%

Gross Profit

Employee Benefit Expenses

Other Operating Expenses

Foreign Exchange Gain / (Loss)

Adj. EBITDA1

2,088

1,783

17.1%

2,008

4.0%

5,916

5,175

14.3%

54.4%

55.3%

54.4%

52.3%

(618)

(821)

685

(558)

10.7%

(555)

11.3%

(1,720)

(1,560)

10.2%

(827)

-0.6%

(841)

-2.4%

(2,365)

(2,308)

2.5%

407

68.0%

628

9.0%

1,893

1,333

42.1%

17.8%

12.6%

17.3%

17.4%

13.5%

Note: 1. EBITDA is adjusted for ESOP costs, accelerated vesting of warrants, call option charge and merger expenses (INR 59mn in Q3FY25 vs. INR 217mn in Q2FY25; Higher in Q2 due to accelerated vesting of warrants) 2. 9MFY24 based on management accounts that have not been subject to limited review by auditors Source: Viyash Life Sciences website published Investor Presentation

Merger Update

Q3FY25: Combined business performance

Q3 FY25 (For the quarter)

Revenue (INR Mn)

EBITDA1 (INR Mn)

SeQuent

Combined

YoY Growth % (Combined)

3,839

3,908

7,747

18.8%

685

494

1,179

66.3%

EBITDA Margin %

17.8%

12.6%

15.2%

+435bps

Net Debt to LTM EBITDA

0.4x

2.1x

1.2x

9MFY25: Combined business performance

9M YTD FY25 (For the quarter)

Revenue (INR Mn)

EBITDA1 (INR Mn)

SeQuent

Combined

YoY Growth % (Combined)

10,872

11,497

22,369

12.0%

1,893

1,424

3,317

66.6%

EBITDA Margin %

17.4%

12.4%

14.8%

+485bps

Net Debt to LTM EBITDA

0.4x

2.1x

1.2x

Merger – Process Update

Merger process status update

• CCI approval received

• Stock exchange NOC process underway - scheme under review by

SEBI and final NOC awaited

• Upon receipt of NOC, NCLT filing to be made

• Other regulatory approvals, if any to follow

Expected timelines for the completion of the merger process as indicated to be 12-15 months (from merger announcement in September 2024).

The same remains unchanged versus prior quarter as process is well on track as per estimated timelines

Synergy Update

Synergy Planning Process on Track

✓ CCI approval received

✓ Senior management

teams have identified & prioritized synergy areas

✓ Integration planning

workshops in focused teams ongoing in Q4FY25

✓ Granular synergy action plan & estimated value to be presented to board in Q1FY26; to be implemented only after receipt of all regulatory approvals

4 Core synergy areas identified

Synergy Realization Timeline (Months)

Area

Till Merger Approval

0-6

6-12

12+

R&D Leverage Viyash’s R&D team & IP focus; resource allocation exercise underway

Manufacturing Optimize group network utilization & procurement. Opportunities identified & action plan created

Sales Tap key relationships across both companies; plan for outreach & discussion prepared

Others Assess shared administrative & support functions

We are here

Appendix

Combined P&L – Snapshot

Particulars

Revenue from Operations Material Consumption Gross Margin % Employee Benefit Expenses Operating Expenses Operating Exchange Gain / (Loss) Adjusted EBITDA % ESOP cost Exceptional Items1 Ind AS 29 Adjustment Exchange Gain / (Loss) Other Income Finance Cost D&A Amortization of Acquisition Intangibles Profit Before Tax Taxes Profit After Tax Adjusted PAT2

Viyash

SeQuent

Combined

FY24 13,110 (6,142) 6,968 53.2% (2,126) (3,206) 34 1,671 12.7% (127) (58) - - 502 (332) (718) (935) 3 (88) (85) 654

9MFY25 10,872 (4,956) 5,916 54.4% (1,720) (2,365) 62 1,893 17.4% (96) (239) - - 98 (201) (532) (705) 218 42 260 1,013

FY24 13,697 (7,597) 6,100 44.5% (2,283) (2,748) - 1,068 7.8% (222) (174) (78) (154) 110 (481) (539) (76) (546) 250 (296) (63)

9MFY25 11,497 (6,121) 5,376 46.8% (1,834) (2,118) - 1,424 12.4% (210) (46) 23 (81) 130 (456) (450) (53) 280 (61) 219 306

FY24 26,807 (13,739) 13,068 48.7% (4,409) (5,954) 34 2,739 10.2% (349) (232) (78) (154) 612 (813) (1,257) (1,011) (543) 162 (381) 591

9MFY25 22,369 (11,077) 11,292 50.5% (3,554) (4,483) 62 3,317 14.8% (306) (285) 23 (81) 228 (657) (982) (758) 498 (19) 479 1,319

Key Notes :

ESOP cost, Exceptional items and amortization of acquisition intangibles are non-cash or non-recurring accounting items that pertain to prior period events: - Exceptional Items include cost of

accelerated vesting for share warrants, call option charge and merger expenses - Amortization of acquisition intangibles in

Viyash is on account of intangibles created during acquisitions done in FY22. This accounting amortization will continue till FY27

Exceptional Items include cost of accelerated vesting for share warrants, call option charge and merger expenses (Viyash) PAT adjusted for Amortization of acquisition intangibles (net of tax) and Exceptional Items

1. 2. Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

For details, feel free to contact:

Yoshita Vora

Company Secretary

Abhishek Singhal

Investor Relations Consultant

+91 22 4111 4777

abhishek@arunya.co.in

investorrelations@sequent.in

Registered Office: 301/A, ‘Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

Websites: www.sequent.in, www.alivira.co | CIN: L99999MH1985PLC036685 | BSE Code:512529 | NSE: SEQUENT | ISIN:

INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

← All Transcripts VIYASH Stock Page →

Sequent Scientific Limited has informed the Exchange about Investor Presentation

Market Movers